Want to see HK:0460 full AI Analyst Report?

Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

1 Followers

0460 Stock Chart & Stats

HK$0.78

-HK$0.01(-1.06%)

At close: Jul 28 4:00 PM EDT

HK$0.78

-HK$0.01(-1.06%)

Day’s Range― - ―

52-Week RangeHK$0.69 - HK$1.79

Previous CloseN/A

Volume33.84M

Average Volume (3M)18.88M

Market Cap

HK$6.76B

Enterprise ValueHK$6.90B

Total Cash (Recent Filing)HK$3.72B

Total Debt (Recent Filing)HK$969.22M

Price to Earnings (P/E)18.4

Beta1.09

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.5%

Share Statistics

EPS (TTM)0.03

Shares Outstanding9,329,999,000

10 Day Avg. Volume21,003,852

30 Day Avg. Volume18,883,541

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)1.72

Price to Sales (P/S)3.85

P/FCF Ratio-46.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$1.11

Price Target Upside42.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.08

Revenue Forecast (FY)HK$3.44B

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryThe sharp 2025 revenue rebound and return to profitability show that the business can regain operating momentum after a difficult period. If this recovery persists, greater sales scale should support reinvestment in pharmaceutical commercialization and improve earnings capacity over the next several quarters.

High Gross MarginsPersistently high gross margins provide meaningful economic value from product sales and create room to absorb operating costs while retaining earnings potential. This margin structure can support investment in research, product lifecycle management, and hospital-channel commercialization if revenue growth remains durable.

Manageable LeverageDeclining debt-to-equity indicates reduced balance-sheet pressure and gives the company a stronger cushion against business volatility. Lower leverage can preserve financial flexibility for pharmaceutical development and commercialization, while limiting the burden that debt service places on future operating cash flows.

Bears Say

Weak Cash GenerationNegative operating and free cash flow alongside positive net income points to weak earnings conversion and reduces internally generated funding. If sustained, this could constrain investment in products and commercialization, increase reliance on external financing, and weaken financial flexibility despite manageable leverage.

Inconsistent Free Cash FlowRepeated periods of negative free cash flow indicate that cash generation has not been consistently reliable across the cycle. This variability makes planning and capital allocation harder, and it may limit the company’s ability to fund growth initiatives from recurring operations without using its balance sheet.

Earnings VolatilityThe sequence of substantial losses followed by a 2025 recovery shows that reported earnings remain volatile rather than firmly established. Such instability makes future profitability less predictable, can weaken confidence in the durability of the turnaround, and reduces the certainty of shareholder returns.

Sihuan Pharmaceutical Holdings Group News

Sihuan’s Anaprazole Shows Strong Phase III Results in Reflux Esophagitis

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm reported Phase...

11d ago

Sihuan Pharmaceutical Wins Hong Kong Approval for Key Medical Aesthetic Products

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical’s subsidiary Meiyan Space has secured...

12d ago

Sihuan Pharmaceutical Invests in Canton Biologics to Build Full-Chain Regenerative Aesthetics Platform

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical, via its subsidiary...

24d ago

Sihuan Pharmaceutical Expands Dongyan Skin Booster Dosage Range to Strengthen Aesthetics Portfolio

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical’s subsidiary Meiyan Space has received...

27d ago

Sihuan’s Xuanzhu Biopharm Strikes Exclusive Bireociclib Deal in Thailand

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical’s non-wholly owned subsidiary Xuanzhu Biopharm...

2M ago

Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical Holdings Group has granted 116,150,000...

2M ago

Sihuan Pharma Launches Share Buyback as Profit Surges on Aesthetics Push

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has stepped up...

2M ago

Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive Director

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical announced that Ms. Miao Guili...

2M ago

Sihuan Pharmaceutical Clarifies Board and Committee Structure

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical Holdings Group Ltd. has announced...

2M ago

Sihuan Pharmaceutical Leans on Aesthetics and Innovation as Generic Drug Margins Erode

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical reported interim revenue of RMB1,161.2...

2M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.69 and its highest was HK$1.79 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$6.76B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 151 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Aug 26, 2026. The company reported HK$0.029 earnings per share for the quarter.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 1.5%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.029 in its last earnings report. Following the earnings report the stock price went down -6.322%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.

Sihuan Pharmaceutical Holdings Group (0460) Earnings & Revenues

Historic Earnings Reports

0460 Stock 12 Month Forecast

Average Price Target

HK$1.11

▲(42.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"HK$2","-1":"-HK$1","-0.25":"-HK$0.25","0.5":"HK$0.5","1.25":"HK$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$1.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$1.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$1.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2026","6":"May<br/>2026","9":"Aug<br/>2026","12":"Nov<br/>2026","25":"Nov<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.725,0.7546153846153846,0.7842307692307692,0.8138461538461539,0.8434615384615385,0.8730769230769231,0.9026923076923077,0.9323076923076923,0.961923076923077,0.9915384615384616,1.021153846153846,1.050769230769231,1.0803846153846155,{"y":1.11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.725,0.7546153846153846,0.7842307692307692,0.8138461538461539,0.8434615384615385,0.8730769230769231,0.9026923076923077,0.9323076923076923,0.961923076923077,0.9915384615384616,1.021153846153846,1.050769230769231,1.0803846153846155,{"y":1.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.725,0.7546153846153846,0.7842307692307692,0.8138461538461539,0.8434615384615385,0.8730769230769231,0.9026923076923077,0.9323076923076923,0.961923076923077,0.9915384615384616,1.021153846153846,1.050769230769231,1.0803846153846155,{"y":1.11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.461,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.333,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.214,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.531,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.451,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.432,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.254,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.958,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.725,"date":1793491200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >